Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C5H7O3.Mg |
Molecular Weight | 254.5196 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Mg++].CC(=O)CCC([O-])=O.CC(=O)CCC([O-])=O
InChI
InChIKey=RECCGACJWKEPOU-UHFFFAOYSA-L
InChI=1S/2C5H8O3.Mg/c2*1-4(6)2-3-5(7)8;/h2*2-3H2,1H3,(H,7,8);/q;;+2/p-2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/126827
Sources: https://www.ncbi.nlm.nih.gov/pubmed/126827
Magnesium levulinate, the magnesium salt of levulinic acid, is a mineral supplement. It has been shown that in some cases of congenital non-spherocytic haemolytic anaemia (CNSHA) with pyruvate kinase deficiency, the primary defect may be related to diminished magnesium-stimulated ATPase activity, followed by elevation of the erythrocyte ATP level. In CNSHA patients the administration of Magnesium levulinate was followed by an increase in PK activity almost to the control value. This may indicate that magnesium ions stimulate deficient ATPase activity and lead to diminution of ATP as a negative effector for other regulatory enzymes.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095186 Sources: https://www.ncbi.nlm.nih.gov/pubmed/126827 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9311401
Five min before induction of anaesthesia, patients received placebo or 200 mg (=8.2 mmol of Mg++) of magnesium laevulinate (Magnesium Diasporal, Protina GmbH) as a slow intravenous bolus.
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A12CC07
Created by
admin on Sat Dec 16 08:31:57 GMT 2023 , Edited by admin on Sat Dec 16 08:31:57 GMT 2023
|
||
|
WHO-VATC |
QA12CC07
Created by
admin on Sat Dec 16 08:31:57 GMT 2023 , Edited by admin on Sat Dec 16 08:31:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
261-299-3
Created by
admin on Sat Dec 16 08:31:57 GMT 2023 , Edited by admin on Sat Dec 16 08:31:57 GMT 2023
|
PRIMARY | |||
|
11586912
Created by
admin on Sat Dec 16 08:31:57 GMT 2023 , Edited by admin on Sat Dec 16 08:31:57 GMT 2023
|
PRIMARY | |||
|
DTXSID90905131
Created by
admin on Sat Dec 16 08:31:57 GMT 2023 , Edited by admin on Sat Dec 16 08:31:57 GMT 2023
|
PRIMARY | |||
|
100000076823
Created by
admin on Sat Dec 16 08:31:57 GMT 2023 , Edited by admin on Sat Dec 16 08:31:57 GMT 2023
|
PRIMARY | |||
|
DB14514
Created by
admin on Sat Dec 16 08:31:57 GMT 2023 , Edited by admin on Sat Dec 16 08:31:57 GMT 2023
|
PRIMARY | |||
|
SUB14432MIG
Created by
admin on Sat Dec 16 08:31:57 GMT 2023 , Edited by admin on Sat Dec 16 08:31:57 GMT 2023
|
PRIMARY | |||
|
58505-81-0
Created by
admin on Sat Dec 16 08:31:57 GMT 2023 , Edited by admin on Sat Dec 16 08:31:57 GMT 2023
|
PRIMARY | |||
|
4593
Created by
admin on Sat Dec 16 08:31:57 GMT 2023 , Edited by admin on Sat Dec 16 08:31:57 GMT 2023
|
PRIMARY | |||
|
DU3I0H5Z4H
Created by
admin on Sat Dec 16 08:31:57 GMT 2023 , Edited by admin on Sat Dec 16 08:31:57 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD